Alexa Kornau

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.

RepRegen Ltd. develops synthetic, biologically-active and tissue engineering products. Its smart biomaterials are designed both to support and to improve cellular growth in vivo. The firm is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in the body. RepRegen's first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. The company was founded in June 2006 and is headquartered in London, GB.